Cargando…
Feasibility Study of Lactobacillus Plantarum 299v Probiotic Supplementation in an Urban Academic Facility among Diverse Pregnant Individuals
(1) Background: Despite iron intake recommendations, over a quarter of pregnant individuals have iron deficiency. Lactobacillus plantarum 299v (LP299V(®)) enhances iron absorption in non-pregnant populations and may have positive effects in pregnancy among those with sufficient iron stores; however,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966742/ https://www.ncbi.nlm.nih.gov/pubmed/36839232 http://dx.doi.org/10.3390/nu15040875 |
Sumario: | (1) Background: Despite iron intake recommendations, over a quarter of pregnant individuals have iron deficiency. Lactobacillus plantarum 299v (LP299V(®)) enhances iron absorption in non-pregnant populations and may have positive effects in pregnancy among those with sufficient iron stores; however, no studies have evaluated the effect of LP299V(®) on maternal and neonatal iron status among individuals at risk for iron deficiency anemia in pregnancy. Thus, this study aims to assess the feasibility and preliminary efficacy of daily oral LP299V(®) maternal supplementation among diverse pregnant individuals. (2) Methods: In this double-blind placebo-controlled randomized supplementation feasibility study, participants were randomized to probiotic LP299V(®) + prenatal vitamin with iron or placebo + prenatal vitamin with iron from 15–20 weeks of gestation through delivery. (3) Results: Of the 20 enrolled and randomized participants, 58% (7/12) from the LP299V(®) group and 75% (6/8) from the placebo group were retained. Adherence to supplementation was 72% for LP299V(®)/placebo and 73% for the prenatal vitamin. A slower decline in maternal hematological and iron parameters across pregnancy was observed in the LP299V(®) group compared to placebo. (4) Conclusions: LP299V(®) may be a tolerable therapy during pregnancy and has the potential to affect maternal and neonatal hematological and iron status. |
---|